Physician-Scientist | Internal Medicine | Postdoctoral Research Fellow @BaptistHealthSF | @akuglobal Alumna | AAMC ID: 14705694 | Views my own
Miami, FL
Joined July 2011
- Tweets1.3K
- Following642
- Followers379
- Likes1.7K
Pinned Tweet
Excited to be applying to Internal Medicine this #Match2027! 🩺
I’m an @akuglobal alumna and currently a physician-scientist in GI oncology at @BaptistHealthSF in Miami. Grateful for everyone who has been part of my journey, and very excited for what’s ahead.
Looking forward to connecting with the wonderful IM community this season!
AAMC ID: 14705694
#InternalMedicine #MedTwitter #Match2027
In Boston for #ASCOQLTY26 this week, presenting two studies using national inpatient data to examine palliative care utilization and malnutrition in cancer hospitalizations.
Sharing a few findings below. Looking forward to connecting with colleagues at the meeting!
@ASCO @MiamiCancerInst @BaptistHealthSF
Presenting our findings at #ASCOQLTY26 from a national analysis of 230,348 GI cancer hospitalizations.
Protein-energy malnutrition was associated with higher inpatient mortality (15.5% vs 3.7%; aOR 3.54), longer hospital stays, and greater costs.
📍 Oct 16 | 12:25–1:45 PM | Hall D, E2
Abstracts available to read online: asco.org/quality/search
@ASCO @Sarbaji85064063
Presenting our second study at #ASCOQLTY26, examining palliative care utilization across 8,915 GI cancer hospitalizations ending in inpatient death.
Only 25.9% had a documented palliative care consultation, which was associated with greater DNR documentation (64.1% vs 19.5%) and lower odds of mechanical ventilation.
📍 Oct 17 | 7:20–8:20 AM EDT
Level 2, Hall D | Poster A7
@ASCO @Sarbaji85064063
#PalliativeCare #QualityOfCare
Excited to share our @eClinicalMed viewpoint on the evolving role of #ctDNA in GI cancers!
thelancet.com/journals/eclin…
We discuss how ctDNA is evolving from a prognostic biomarker to a predictive tool through prospective ctDNA-guided trials, with the future integrating serial monitoring, multi-omics, imaging, clinical data, and AI to advance precision oncology. Grateful to all my co-authors for this collaboration.
@Sarbaji85064063 @BrainTumorDoc @OncBrothers @oncodaily @OncoDailyGI @Onco_Nexus @OncUpdates @TheLancetOncol #GIOncology #PrecisionOncology #CancerResearch
Azza Sarfraz retweeted
1/2:
Excited to share our new @eClinicalMed viewpoint on the evolving role of ctDNA in GI cancers.
ctDNA has emerged as a powerful prognostic marker—but its greatest potential lies in prospective ctDNA-guided trials to move the field from prognosis to prediction.
Azza Sarfraz retweeted
Excited to share our recent paper in @AnnSurgOncol from @OhioStateSurg and @CleveClinicFL.
Postoperative complications have a variable prognostic impact after surgery for #CRLM, depending on both complication severity and the underlying tumor biology.
@timpawlik @AmCollSurgeons – at Weston, FL
Honored, excited, and incredibly grateful to have contributed to 3 presentations at #ASCO26 this year!
🏅 ASCO AYA Featured Poster on multimodal risk phenotyping in early-onset colorectal cancer
📈 Poster on leadership attainment among participants in the ASCO Leadership Development Program
🎤 Rapid Oral Presentation on gender representation in first and senior authorship of phase III solid tumor trials
A special congratulations to my mentor @Sarbaji85064063 on being selected for the Leadership Development Program. Thank you @BrainTumorDoc @ZouinaS @QidwaiKhalid @nihanakkoc @BaptistHealthSF for your support!
#ASCO26 #CancerResearch #Oncology #meded #gender #AYA
Azza Sarfraz retweeted
🎯 What predicts leadership attainment in oncology?
Congrats to Sarah Abraham on presenting this ASCO 2026 poster on outcomes among @ASCO Leadership Development Program graduates. The study highlights associations between leadership attainment, scholarly productivity, and geographic region.
As a current #ASCOLDP participant, I found these findings especially meaningful
Remarkable achievement for Sarah to present an ASCO poster as a medical student!
@AzzaSarfraz @ZouinaS @nihanakkoc @BrainTumorDoc @BaptistHealthSF @MiamiCancerInst @FIU
#ASCO2026 #OncologyLeadership #LeadershipDevelopment
Azza Sarfraz retweeted
Excited to kick off Day 1 at ASCO 2026! ✨☀️
Looking forward to engaging discussions, groundbreaking research, and opportunities to connect with colleagues advancing cancer care worldwide.
Grateful to be part of this incredible community dedicated to improving outcomes for patients. #ASCO26 #Chicago 🍍 – at Chicago, IL
Honored to contribute to this work and excited to see it presented at #ASCO2026. Grateful to Dr. Mukherjee, our collaborators, and the outstanding team at Miami Cancer Institute for the opportunity. Looking forward to a great meeting and the research ahead.
🚀 ASCO 2026 is officially underway!
Excited to kick off the meeting by presenting our study on authorship trends in Phase III solid tumor clinical trials presented at #ASCO from 2015–2025.
Grateful to @ASCO for selecting our work and to @AzzaSarfraz and our medical students at @FIU for their incredible contributions that made this project possible.
And this is just Day 1.
Our GI Cancer team at @BaptistHealthSF @MiamiCancerInst will be presenting multiple posters and research updates throughout the meeting. More to come—stay tuned!
@BrainTumorDoc @BrunaPellini @ZouinaS @sawyer_bawek @nihanakkoc
#ASCO2026 #Oncology #CancerResearch #ClinicalTrials #GICancer
Azza Sarfraz retweeted
How do we close the gap between promising clinical trial data and real-world patient care?
Looking forward to joining an outstanding group of colleagues at the Frontiers Meets Frontlines satellite event during #ASCO2026 to discuss emerging advances in GI oncology and their practical application in the clinic.
Thanks to @TotalHealthConf , @Onco_Nexus, and @GIMedOnc for the invitation.
Honored to share the panel with:
@YJanjigianMD
@marklewismd
If you’re attending ASCO, please join us in person or virtually for what should be a highly engaging discussion.
@BaptistHealthSF @BHCancerCare @MiamiCancerInst
#GIOncology #ClinicalTrials #ASCO
🚨 New publication!
In 38,000+ patients nationwide, we show that pregnancy meaningfully alters cancer treatment pathways and impacts maternal and neonatal outcomes 🤰📊
Proud of this collaborative work with @timpawlik and @OhioStateSurg.
🔗 authors.elsevier.com/c/1mdad…
#SurgOnc #WomensHealth #Oncology
Azza Sarfraz retweeted
Chief of GI oncology Dr. Sarbajit Mukherjee discusses new implications with ADCs for GI cancers.
#MCIPrecisionOncology @Sarbaji85064063
Outstanding and highly informative talk by Dr. @Sarbaji85064063 on ADCs in GI cancers, covering target expression patterns, biologic and trial design challenges, and next-generation strategies. A masterclass on where the field is headed. A truly insightful session!
@MiamiCancerInst @BrainTumorDoc @oncodaily @OncoAlert #MCIPrecisionOncology
Azza Sarfraz retweeted
⭐️Amazing talk on “Targeted therapies in Pancreatic Cancer” - KRAS, NTRK, BRAF, RET and much much more by @DrShubhamPant @MDAndersonNews ! This is such an exciting time in pancreatic cancer research- see the waterfall plot to KRAS therapy ! @Aiims1742 @BrainTumorDoc @MiamiCancerInst @GIcancerDoc
Azza Sarfraz retweeted
New @CellCellPress
The hallmarks of cancer, refined from the original concepts 25 years ago, as an outgrowth of our expanding knowledge base
cell.com/cell/fulltext/S0092…
Such an insightful and informative session! So glad I had the opportunity to meet you, Dr. @VivekSubbiah. Thank you for the inspiring discussion on precision oncology. @ZouinaS @BrainTumorDoc
⭐️Such a delight to deliver the keynote on “Re-imagining the Precision Oncology Paradigm” 👉🏼 discussing the paper published in @AACR @CD_AACR “Rethinking Cancer Drug Development through Tumor-agnostic Precision Medicine”! Fantastic Friday morning with an amazing panel discussion session & terrific colleagues @BrainTumorDoc @chadinabhan @neerajaiims @OncoAlert @oncodaily @MiamiCancerInst
aacrjournals.org/cancerdisco…
